CDTX

Cidara Therapeutics, Inc.

—

Insider Sentiment

Last purchase: 2025-06-26
Last sale: 2025-12-10
Shares purchased (TTM): 2,273,777
Shares sold (TTM): 13,870

Buy ratio (TTM)99.4%

Institutional Sentiment

As of: 2025-12-31
Institutional shares owned: 32,284,766
Shares outstanding: 26,882,366
Ownership: 120.10%

+11.85% Y/Y

Earnings Market Reaction

Filing date: 2025-11-06
Price on filing date: —
1-month reaction: 122.91%
3-month reaction: …

Drift continued2/10 (20%)

Faded / reversed8/10 (80%)

Export data

Recent filings

10-Q2025-09-30Filed 2025-11-06
10-Q2025-06-30Filed 2025-08-07
10-Q2025-03-31Filed 2025-05-08
10-K2024-12-31Filed 2025-03-06
10-Q2024-09-30Filed 2024-11-07
10-Q2024-06-30Filed 2024-08-13
10-Q2024-03-31Filed 2024-05-15
10-K2023-12-31Filed 2024-04-22
10-Q2023-09-30Filed 2023-11-02
10-Q2023-06-30Filed 2023-08-03
10-Q2023-03-31Filed 2023-05-11
10-K2022-12-31Filed 2023-03-23

Financial statements beyond 3 years are for subscribers only.

Unlock 17+ years of income statements, balance sheets, and cash flow statements

Start 7-day free trial

Balance Sheet

Values in millions ($)

Line item	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31
Assets Current
Cash And Cash Equivalents At Carrying Value	294	511	168	190	127	164	29	36	49	50	48	33
Restricted Cash Current	6	6	6	6	-	-	-	0	-	-	-	0
Available For Sale Securities Debt Securities Current	126	-	-	-	-	-	-	-	-	-	-	-
Accounts Receivable Net Current	2	2	2	2	2	2	7	14	3	5	26	6
Inventory Net	-	-	-	-	-	-	7	6	2	2	-	0
Prepaid Expense And Other Assets Current	15	13	13	13	28	2	3	2	4	4	6	7
Assets Of Disposal Group Including Discontinued Operation Current	-	-	-	0	0	0	-	9	-	-	-	-
Assets Current	443	532	189	211	157	169	47	61	58	62	79	45
Property Plant And Equipment Net	0	0	0	1	1	1	1	1	1	0	0	0
Finance Lease Right Of Use Asset	0	0	0	1	1	1	1	1	-	-	-	0
Operating Lease Right Of Use Asset	2	2	2	3	3	3	4	4	4	4	1	1
Available For Sale Securities Debt Securities Noncurrent	50	-	-	-	-	-	-	-	-	-	-	-
Other Assets Noncurrent	24	0	0	0	1	0	1	0	1	1	1	1
Disposal Group Including Discontinued Operation Assets Noncurrent	-	-	-	0	0	0	-	1	-	-	-	-
Assets	519	534	192	215	162	173	53	67	63	68	82	47
Liabilities Current
Deferred Revenue Current	-	-	-	-	-	-	-	-	-	15	-	-
Accounts Payable Current	4	2	5	4	3	2	5	4	4	2	4	1
Accrued Liabilities Current	71	11	20	13	9	6	8	14	12	10	9	8
Accrual For Taxes Other Than Income Taxes Current	15	15	21	26	26	26	21	18	-	-	-	12
Loans Payable Current	-	-	-	-	-	-	-	-	-	-	-	0
Employee Related Liabilities Current	4	3	2	5	5	4	6	5	4	4	6	5
Finance Lease Liability Current	0	0	0	0	0	0	0	0	-	-	-	0
Operating Lease Liability Current	2	1	1	1	1	1	1	1	1	1	1	1
Liabilities Of Disposal Group Including Discontinued Operation Current	-	-	-	0	0	0	-	25	-	-	-	-
Liabilities Current	96	32	49	50	44	40	65	67	36	31	36	41
Finance Lease Liability Noncurrent	0	0	0	0	0	0	1	1	-	-	-	0
Operating Lease Liability Noncurrent	0	1	1	2	2	2	3	3	3	4	-	0
Liabilities Of Disposal Group Including Discontinued Operation Noncurrent	-	-	-	0	0	0	-	4	-	-	-	-
Liabilities	96	33	50	51	47	42	70	75	55	53	55	62
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,166	1,162	776	775	675	674	434	433	432	432	431	404
Accumulated Other Comprehensive Income Loss Net Of Tax	-0	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings Accumulated Deficit	-744	-660	-635	-611	-559	-543	-452	-441	-424	-416	-404	-419
Stockholders Equity	422	501	142	163	116	131	-18	-8	-6	2	15	-14
Liabilities And Stockholders Equity	519	534	192	215	162	173	53	67	63	68	82	47
Series A Convertible Voting Preferred Stock	0	0	0	0	-0	0	-	0	-	-	-	-
Series X Convertible Preferred Stock	0	0	0	0	0	0	2	0	0	0	2	0
Preferred Stock Par Or Stated Value Per Share	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Common Stock Par Or Stated Value Per Share	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Common Stock Shares Authorized	100	50	50	50	50	20	200	20	200	200	200	200
Common Stock Shares Issued	29	23	12	11	7	5	5	5	5	5	5	4
Shares Outstanding	29	23	12	11	7	5	5	5	5	5	5	4

Select a line item above to chart it.

Recent filings

10-Q2025-09-30Filed 2025-11-06
10-Q2025-06-30Filed 2025-08-07
10-Q2025-03-31Filed 2025-05-08
10-K2024-12-31Filed 2025-03-06
10-Q2024-09-30Filed 2024-11-07
10-Q2024-06-30Filed 2024-08-13
10-Q2024-03-31Filed 2024-05-15
10-K2023-12-31Filed 2024-04-22
10-Q2023-09-30Filed 2023-11-02
10-Q2023-06-30Filed 2023-08-03
10-Q2023-03-31Filed 2023-05-11
10-K2022-12-31Filed 2023-03-23

Financial statements beyond 3 years are for subscribers only.

Unlock 17+ years of income statements, balance sheets, and cash flow statements

Start 7-day free trial

Cidara Therapeutics, Inc. (CDTX) — SEC Financial Statements & Analysis

Cidara Therapeutics, Inc. (CDTX) is a biological products, (no diagnostic substances) company, incorporated in DE. Cidara Therapeutics, Inc. trades on Nasdaq as: CDTX. Cidara Therapeutics, Inc. (CDTX)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-06. Based on that filing, On profitability, Cidara Therapeutics, Inc. posts an operating margin of 10548.46%, a net margin of 9969.67%, a Return on Equity (ROE) of -68.67%, a Return on Assets (ROA) of -54.26%, and a Return on Invested Capital (ROIC) of -353.51%. Per share, it reports EPS of $-6.87, diluted EPS of $-6.87, free cash flow per share of $-4.95, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -94.38% year-over-year, net income growth of 51.84% year-over-year, and EPS growth of -63.12% year-over-year. On the balance sheet, it maintains a current ratio of 4.62x, a quick ratio of 4.47x, working capital of $346.98M, a debt-to-equity ratio of 0.23x, a debt ratio of 0.19, an interest coverage ratio of -18.14x, free cash flow of $-132.94M (TTM), and net debt of $-299.99M. Figures sourced from SEC EDGAR.

EPS TTM: $-6.87
ROE TTM: -68.67%
ROA TTM: -54.26%
Debt To Equity: 0.23x
Free Cash Flow TTM: $-132.94M
Net Revenue TTM Growth 1Y: -94.38%

Data as of 2025-09-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Cidara Therapeutics, Inc. in?

Cidara Therapeutics, Inc. (CDTX) operates in the Biological Products, (No Diagnostic Substances) industry.

What exchange does CDTX trade on?

Cidara Therapeutics, Inc. (CDTX) trades on the Nasdaq.

Where is Cidara Therapeutics, Inc. incorporated?

Cidara Therapeutics, Inc. is incorporated in DE.

When was Cidara Therapeutics, Inc. (CDTX)'s most recent SEC filing?

Cidara Therapeutics, Inc. (CDTX)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-06.

What is CDTX's EPS (earnings per share)?

Cidara Therapeutics, Inc. (CDTX)'s trailing twelve month EPS is $-6.87 as of 2025-09-30.

What is CDTX's ROE (return on equity)?

Cidara Therapeutics, Inc. (CDTX)'s trailing twelve month Return on Equity (ROE) is -68.67% as of 2025-09-30.

What is CDTX's ROA (return on assets)?

Cidara Therapeutics, Inc. (CDTX)'s trailing twelve month Return on Assets (ROA) is -54.26% as of 2025-09-30.

What is CDTX's ROIC (return on invested capital)?

Cidara Therapeutics, Inc. (CDTX)'s trailing twelve month Return on Invested Capital (ROIC) is -353.51% as of 2025-09-30.

Wall Street's data.
Main Street's price.

Start 7-day free trial

CDTX

Company Information

Insider Sentiment

Institutional Sentiment

Earnings Market Reaction

Recent filings

Recent filings

Cidara Therapeutics, Inc. (CDTX) — SEC Financial Statements & Analysis

Frequently Asked Questions

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.